Nanobiotix S.A.
Nanobiotix S.A. is a clinical-stage biotechnology company developing nanotechnology-based therapeutic candidates, with its core programs centered on oncology and additional platform applications in bioavailability, biodistribution, and central nervous system disorders. The company is headquartered in Paris, France, and has a U.S. subsidiary in Cambridge, Massachusetts, while its shares trade on Euronext Paris and Nasdaq.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueClinical-stage cancer therapies and related development programs, including NBTXR3.
Nanotechnology platforms used to generate therapeutic candidates across multiple indications.
Rights and partner-supported development activities tied to collaborative programs.
Customers
Nanobiotix does not sell a broad commercial product portfolio; its direct counterparts are typically pharmaceutical and biotechnology partners, academic research institutions, and clinical collaborators involved in drug development. The end beneficiaries are patients in oncology and other therapeutic areas, while partner organizations use the company’s platforms and candidates to advance clinical programs and potential future approvals.
Companies collaborating on development, clinical testing, and potential commercialization of NBTXR3 and related assets.
Research institutions and cancer centers that sponsor or conduct clinical studies using the company’s platforms.
Patients enrolled in studies for oncology and other indications, enabling proof-of-concept and regulatory progress.
Third parties that could adopt or monetize the company’s platform technologies in new indications.
Strategy
The company’s strategy is built around advancing NBTXR3 and extending its nanotechnology platforms through partnerships, sponsored studies, and broader indication coverage. This approach spreads development across multiple programs while leveraging external collaborators to expand the clinical and commercial potential of the platform.
Clinical progress is the main value driver for a late-stage biotechnology company and underpins future approval opportunities.
Partnerships broaden trial reach, share development burden, and increase the number of indications being evaluated.
Diversifying beyond a single lead asset can widen the company’s addressable opportunity and reduce reliance on one program.
Geography
Nanobiotix is headquartered in Paris and operates internationally through a U.S. subsidiary in Cambridge, Massachusetts. Its shares are listed in Europe and the United States, and its development model depends on cross-border clinical collaboration and regulatory pathways rather than manufacturing geography.
Risks
Nanobiotix faces the typical risks of a clinical-stage biotech company: trial failure, regulatory delays, partner dependence, and the need to fund development before any commercial revenue is established. Its press releases also highlight cash runway assumptions, making financing access and execution on study milestones important to the business model.
- Clinical development failureImpact: CriticalLikelihood: High
The company’s value depends on successful trial readouts and regulatory acceptance of NBTXR3 and related programs.
Exposure: NBTXR3 and sponsored oncology studies
- Financing and cash runway riskImpact: HighLikelihood: High
Development-stage biotechnology companies consume cash before product sales, and the company explicitly flags runway assumptions.
Exposure: General corporate funding and pipeline advancement
- Partner dependenceImpact: HighLikelihood: Medium
Clinical expansion relies on collaborators and sponsors, which can affect timing, scope, and prioritization of studies.
Exposure: MD Anderson collaboration and other external programs
- Regulatory and approval riskImpact: HighLikelihood: Medium
Even positive clinical data may not translate into approval without sufficient safety, efficacy, and manufacturing evidence.
Exposure: Oncology product candidate development
Accounting
Judgemental itemsClinical-stage companies expense most development costs as incurred, making trial timing a major driver of quarterly results.
Impact: Affects operating loss and comparability across periods
Partner agreements may include upfront, milestone, or cost-sharing elements that require judgment on recognition timing.
Impact: Can create uneven revenue and income recognition
Biotech companies often rely on equity incentives, which can be a meaningful non-cash expense.
Impact: Affects operating expenses and diluted share counts
Similar listed companies
Publicly listed companies with a comparable business focus.
Eupraxia Pharmaceuticals Inc
EPRX · Pharmaceutical Preparations
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
CNBX Pharmaceuticals Inc.
CNBX · Pharmaceutical Preparations
Anavex Life Sciences Corp
AVXL · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026